Latest News on CYTK

Financial News Based On Company


Advertisement
Advertisement

Cytokinetics (CYTK) Stock Price, Chart & Analysis

https://www.debelegger.nl/en/stock/CYTK.US
This article provides a detailed analysis of Cytokinetics (CYTK) stock, including its current price, key financial figures, and analyst expectations. It highlights the company's strong revenue growth but notes its lack of profitability and dividend payments. The analysis also includes various financial ratios, a quality score, and a "Belegger score" based on Buffett and Lynch methods, concluding with potential future price scenarios.

Four entities report the same 10.7M Cytokinetics (CYTK) shares in an amended stake disclosure.

https://www.stocktitan.net/sec-filings/CYTK/schedule-13g-a-cytokinetics-inc-amended-passive-investment-disclosure-faa786261c94.html
Wellington Management Group LLP, Wellington Group Holdings LLP, Wellington Investment Advisors Holdings LLP, and Wellington Management Company LLP have filed an amended SCHEDULE 13G/A, reporting beneficial ownership of 10,742,652 shares of Cytokinetics, Incorporated (CYTK) common stock. This represents a 7.73% ownership stake in the company. The filing details shared voting and dispositive powers among the entities, with slight variations in reported ownership percentages on the cover pages.

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

https://www.globenewswire.com/news-release/2026/11/16/3404076/35409/en/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html
Cytokinetics announced it granted stock options for 64,110 shares and 42,496 restricted stock units (RSUs) to 18 new employees as a material inducement for their employment. These grants, made on November 13, 2026, are in accordance with Nasdaq Listing Rule 5635(c)(4) and are subject to vesting schedules tied to continued service. The stock options have an exercise price of $56.13 per share.

Cytokinetics stock hits 52-week low at $53.53

https://www.investing.com/news/company-news/cytokinetics-stock-hits-52week-low-at-5353-93CH-5030359
Cytokinetics Inc.'s stock recently reached a 52-week low of $53.57, down 39% from its 52-week high and approximately 15.5% over the past year. Despite this, InvestingPro analysis suggests the stock is undervalued with anticipated sales growth and impressive 30% revenue growth over the last twelve months. The company recently surpassed third-quarter 2026 financial expectations, driven by strong MYQORZO sales, posting a narrower loss than analysts predicted.

FDA Approval for MYQORZO issued to CYTOKINETICS

https://www.quantisnow.com/insight/fda-approval-for-myqorzo-issued-to-cytokinetics-6792080
The FDA issued a supplemental approval for Cytokinetics' MYQORZO (aficamten) on November 13, 2026, which is a labeling change supported by clinical data. This drug was previously approved on December 19, 2025, and this latest update indicates continued regulatory progress. However, the specific details of the label change and its commercial impact remain unclear to shareholders.
Advertisement

Weekly Recap: FDA adds MAPLE-HCM results and ACACIA-HCM reports benefits

https://www.tradingview.com/news/tradingview:ae04e1a03b0eb:0-weekly-recap-fda-adds-maple-hcm-results-and-acacia-hcm-reports-benefits/
Cytokinetics (NASDAQ:CYTK) announced that the FDA approved a MYQORZO label update, incorporating Phase 3 MAPLE-HCM results showing aficamten's superior performance over metoprolol. The company also reported positive Phase 3 ACACIA-HCM data, with aficamten improving heart measures, though benefits waned post-treatment. Cytokinetics saw a 76% quarter-over-quarter revenue increase and prioritized a year-end filing for nonobstructive hypertrophic cardiomyopathy.

FDA approves label update for Cytokinetics’ heart drug MYQORZO

https://www.investing.com/news/company-news/fda-approves-label-update-for-cytokinetics-heart-drug-myqorzo-93CH-5028735
The FDA has approved an updated label for Cytokinetics' heart drug MYQORZO (aficamten), including data from the MAPLE-HCM Phase 3 trial. This update incorporates comparative data against metoprolol, demonstrating MYQORZO's effectiveness in improving peak oxygen uptake and other secondary endpoints in adults with symptomatic obstructive hypertrophic cardiomyopathy. The drug carries a boxed warning due to the risk of heart failure and requires echocardiogram assessments during treatment.

Cytokinetics’ MYQORZO Gains Ground as Company Plans Push Into New Heart-Disease Market

https://www.tradingview.com/news/marketbeat:ef9590808094b:0-cytokinetics-myqorzo-gains-ground-as-company-plans-push-into-new-heart-disease-market/
Cytokinetics' MYQORZO is gaining market share and prescriber adoption, with revenue up 76% from the previous quarter and patient dispenses exceeding 2,800. The company plans regulatory submissions to expand the use of aficamten, the drug's active ingredient, into new heart-disease markets, including non-obstructive hypertrophic cardiomyopathy. Cytokinetics also aims to gather long-term safety data to potentially ease risk evaluation and mitigation strategy requirements, supported by $1.6 billion in cash and investments for launches and pipeline development.

FDA Decision Due Today on Heart Drug Myqorzo: Metoprolol Trial Win Meets Boxed Warning, Payer Rules

https://www.techtimes.com/articles/330716/20261114/fda-decision-due-today-heart-drug-myqorzo-metoprolol-trial-win-meets-boxed-warning-payer-rules.htm
The FDA was expected to rule on November 14, 2026, regarding Cytokinetics' supplemental application to add MAPLE-HCM trial results for its heart drug MYQORZO (aficamten) to the existing label. While the trial showed aficamten outperformed metoprolol in patients with obstructive hypertrophic cardiomyopathy (oHCM), the drug already carries a boxed warning for heart failure, and insurers still require prior beta-blocker use. Cytokinetics is not pushing for first-line use of MYQORZO, acknowledging the current payer and guideline limitations despite the positive trial data.

Does New Aficamten Data Change The Bull Case For Cytokinetics Stock (CYTK)?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cytk/cytokinetics/news/does-new-aficamten-data-change-the-bull-case-for-cytokinetic
Cytokinetics recently reported Q3 2026 results and presented new data for its drug aficamten, indicating it may positively influence cardiac structure and patient health status in hypertrophic cardiomyopathy. While the company faces a significant Q3 loss, the new data supports the potential for a broader cardiomyopathy franchise and label expansion for aficamten, potentially strengthening the bull case despite safety concerns and high SG&A costs. Analysts are projecting substantial revenue growth and eventual profitability, with some more cautious voices potentially shifting their outlook based on these new findings.
Advertisement

Cytokinetics director B. Lynne Parshall sells $273,634 in shares

https://www.investing.com/news/insider-trading-news/cytokinetics-director-b-lynne-parshall-sells-273634-in-shares-93CH-5024399
B. Lynne Parshall, a director at Cytokinetics Inc. (NASDAQ:CYTK), recently sold 5,000 shares of common stock for a total of $273,634. These transactions occurred on November 9, 2026, with share prices ranging from $53.72 to $55.71. Following the sale, Ms. Parshall directly holds 5,784 shares, and the company's stock is currently trading at $56.16, near its 52-week low.

Form 4 Cytokinetics Inc: B. Lynne Parshall (Director) For: 9 November By Investing.com

https://in.investing.com/news/stock-market-news/form-4-cytokinetics-inc-b-lynne-parshall-director-for-9-november-93CH-5702048
This article reports on a Form 4 filing for Cytokinetics Inc (CYTK), detailing a transaction by B. Lynne Parshall, a Director, on November 9th. The article is a brief news item from Investing.com, typical for reporting insider trading activities.

Is Cytokinetics (CYTK) Undervalued On New Aficamten Data?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cytk/cytokinetics/news/is-cytokinetics-cytk-undervalued-on-new-aficamten-data
Cytokinetics (CYTK) is back in focus due to new aficamten data presented at medical sessions, which highlighted cardiac remodeling, biomarker changes, and quality-of-life outcomes in patients with hypertrophic cardiomyopathy. Despite recent share price volatility, the company's valuation is seen as 46% undervalued by analysts, with a fair value of $107.80 against a current price of $58.53, based on projections of future revenue and earnings. However, this optimism is tempered by risks within its pipeline, current financial losses, and a projected timeline for profitability.

A Trio Of FDA Verdicts: BioXcel, Cytokinetics And Summit Await Key Decisions On Nov.14

https://www.rttnews.com/3713154/a-trio-of-fda-verdicts-bioxcel-cytokinetics-and-summit-await-key-decisions-on-nov-14.aspx
Three biotechnology companies—BioXcel Therapeutics Inc., Cytokinetics Inc., and Summit Therapeutics Inc.—are awaiting crucial FDA decisions on November 14, 2026. These decisions pertain to supplemental New Drug Applications for BioXcel's IGALMI and Cytokinetics' MYQORZO (Aficamten), and a Biologics License Application for Summit's Ivonescimab. This date marks a significant regulatory milestone for investors in neuroscience, cardiovascular disease, and oncology.

Aficamten Improved Quality of Life for Some Patients With Non-Obstructive HCM—but the Benefit Was Modest and Requires Ongoing Monitoring

https://www.medicaldaily.com/aficamten-non-obstructive-hcm-quality-life-481071
Cytokinetics announced new analyses from the ACACIA-HCM trial, showing that aficamten improved a broad quality-of-life score by 4.0 points over placebo in patients with non-obstructive hypertrophic cardiomyopathy. While the benefits were modest and require ongoing monitoring, these findings are significant as there is currently no approved medication specifically for this condition. Cytokinetics plans to seek FDA approval for aficamten for non-obstructive HCM in late 2026.
Advertisement

Form 144 CYTOKINETICS For: 10 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-144-cytokinetics-for-10-november-93CH-4945237
This article announces the filing of Form 144 for CYTOKINETICS, dated November 10. Form 144 is a notice of the intent to sell restricted securities. The brief article, published by Investing.com, includes CYTK's stock performance and general market data.

B Lynne Parshall proposes selling 5,000 Cytokinetics (CYTK) shares.

https://www.stocktitan.net/sec-filings/CYTK/144-cytokinetics-inc-sec-filing-76f006424b97.html
B Lynne Parshall, a director at Cytokinetics Inc. (CYTK), has reported a proposed sale of 5,000 common shares with an aggregate market value of $268,450, scheduled for approximately November 9, 2026. These shares were initially acquired as restricted stock units on May 14, 2026. The notice also details a prior sale on September 1, 2026, of 5,000 common shares that yielded gross proceeds of $357,404.

Temporary heart-function drops affected 12 of 410 patients; none were linked to heart-failure stays or deaths.

https://www.stocktitan.net/news/CYTK/cytokinetics-announces-additional-data-related-to-aficamten-ycpk5vmtbstm.html
Cytokinetics announced new data for its drug aficamten, presented at medical sessions. In non-obstructive hypertrophic cardiomyopathy (nHCM), aficamten led to significant reductions in left ventricular mass and wall thickness, and improved patient-reported health scores, though these benefits declined after treatment withdrawal. For obstructive hypertrophic cardiomyopathy (oHCM), long-term safety data showed that 12 out of 410 patients experienced temporary, reversible drops in heart pumping function (LVEF <50%), with no associated hospitalizations or deaths due to heart failure.

Cytokinetics Announces Additional Data Related to Aficamten Presented at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions Held in Collaboration with the American Heart Association Scientific Sessions 2026

https://ir.cytokinetics.com/press-releases/press-release-details/2026/Cytokinetics-Announces-Additional-Data-Related-to-Aficamten-Presented-at-the-Hypertrophic-Cardiomyopathy-Medical-Society-HCMS-Scientific-Sessions-Held-in-Collaboration-with-the-American-Heart-Association-Scientific-Sessions-2026/default.aspx
Cytokinetics announced new data for aficamten at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions. The data from ACACIA-HCM showed that aficamten led to favorable cardiac remodeling and significant improvements in patient-reported health status in non-obstructive hypertrophic cardiomyopathy (nHCM) patients. Additionally, long-term data from FOREST-HCM highlighted the sustained safety and tolerability of aficamten in obstructive HCM (oHCM) patients, with transient and reversible reductions in left ventricular ejection fraction.

Cytokinetics, Incorporated (NASDAQ:CYTK) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cytk/cytokinetics/news/cytokinetics-incorporated-nasdaqcytk-third-quarter-results-h
Cytokinetics (NASDAQ:CYTK) reported strong third-quarter results with revenues of US$48m, beating expectations. Analysts are now forecasting revenues of US$443.0m in 2027, a 291% improvement, and a narrowing of losses to US$4.51 per share. Despite increased revenue estimates, the consensus price target remains unchanged at US$107, indicating that ongoing losses continue to weigh on valuation.
Advertisement

Cytokinetics, Incorporated 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:CYTK) 2026-11-08

https://seekingalpha.com/article/4964882-cytokinetics-incorporated-2026-q3-results-earnings-call-presentation?source=feed_all_articles
Cytokinetics, Incorporated (NASDAQ:CYTK) has published its Q3 2026 earnings call presentation. The company reported an EPS of -$1.37, beating estimates by $0.03, and revenue of $47.56M, which represents a significant 2,356.46% year-over-year increase and beat estimates by $5.82M. This article provides access to the slide deck accompanying their earnings call.

Precision Trading with Cytokinetics Incorporated (CYTK) Risk Zones

https://news.stocktradersdaily.com/news_release/149/Precision_Trading_with_Cytokinetics_Incorporated_CYTK_Risk_Zones_110626022802_1793993282.html
This article provides a detailed analysis of Cytokinetics Incorporated (CYTK), highlighting weak near-term sentiment despite long-term strength. It outlines three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis also includes multi-timeframe signal analysis, showing support and resistance levels across different time horizons.

Cytokinetics (CYTK) Stock Looks Hard To Judge On Book Value

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cytk/cytokinetics/news/cytokinetics-cytk-stock-looks-hard-to-judge-on-book-value
Cytokinetics (CYTK) stock's recent performance makes it challenging to evaluate based on book value, especially since its P/B ratio is negative due to negative shareholder equity. Investors are focusing on the company's future potential, including its pipeline, cash runway, and trial data, rather than its current accounting capital. Analyst narratives suggest the stock might be undervalued, provided its commercial franchise for heart disease treatments develops successfully, though recent insider share sales introduce an element of scrutiny.

Cytokinetics stock hits 52-week low at 58.0 USD

https://www.investing.com/news/company-news/cytokinetics-stock-hits-52week-low-at-580-usd-93CH-5004893
Cytokinetics Inc. stock recently hit a 52-week low of $58.05, trading down 34% from its high, reflecting a challenging year for the biopharmaceutical firm. Despite this, the company reported third-quarter 2026 results that exceeded Wall Street expectations, driven by strong MYQORZO sales and a narrower-than-anticipated adjusted loss. InvestingPro analysis suggests the stock is undervalued relative to its Fair Value, even though the company is not yet profitable.

Cytokinetics (CYTK) Could Be 41% Undervalued Following Strong Q3 And Aficamten Data

https://sg.finance.yahoo.com/news/cytokinetics-cytk-could-41-undervalued-101142772.html
Cytokinetics (CYTK) is back in focus after a strong Q3 update, reporting US$47.56 million in revenue and fresh late-stage data for its heart drug aficamten. Despite a recent share price pullback, the stock has shown significant long-term gains, with analysts suggesting it is 41% undervalued at a fair value of $107.80. This valuation depends on successful execution of MYQORZO and aficamten, as well as navigating potential regulatory setbacks and managing high expenses.
Advertisement

Cytokinetics (CYTK) Tops Q3 EPS by 8c, Beats on Revenue

https://www.streetinsider.com/Earnings/Cytokinetics+%28CYTK%29+Tops+Q3+EPS+by+8c%2C+Beats+on+Revenue/27289705.html
Cytokinetics (NASDAQ: CYTK) reported its Q3 earnings, surpassing analyst expectations with an EPS of ($1.37), which was $0.08 better than the estimated ($1.45). The company also exceeded revenue forecasts, bringing in $47.6 million against a consensus estimate of $40.61 million. Cytokinetics reaffirmed its full-year 2026 financial guidance for GAAP combined R&D and SG&A expenses.

Cytokinetics (CYTK) Earnings Reframe Its Valuation As Revenue Improves And Losses Narrow

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cytk/cytokinetics/news/cytokinetics-cytk-earnings-reframe-its-valuation-as-revenue
Cytokinetics (CYTK) is seeing its valuation re-evaluated after reporting third-quarter revenue of US$47.56 million and a net loss of US$190.07 million. Despite recent share price fluctuations, the company is viewed by many as undervalued, with a fair value of $107.80 compared to its last close of $63.60, primarily due to its cardiomyopathy drug pipeline and proprietary muscle biology platform. Investors are now weighing the potential for future portfolio growth and reduced risk against ongoing high operating costs and trial outcomes.

Cytokinetics Q3 Earnings Call Highlights

https://www.tradingview.com/news/marketbeat:7167169fb094b:0-cytokinetics-q3-earnings-call-highlights/
Cytokinetics reported strong Q3 net revenue of $44.5 million for its heart drug MYQORZO, a 76% increase from the previous quarter, as the company prepares regulatory submissions to expand the treatment's use. The company's launch of MYQORZO continues to exceed expectations, with significant growth in prescriptions and patient demand, and plans for further expansion in the U.S. and Europe. Cytokinetics also provided updates on its pipeline, including trials for nHCM and other cardiovascular conditions, while narrowing its net loss despite increased launch-related spending.

Form 4 Cytokinetics Inc: Fady Ibraham Malik (EVP Research & Development) For: 3 November By Investing.com

https://in.investing.com/news/stock-market-news/form-4-cytokinetics-inc-fady-ibraham-malik-evp-research--development-for-3-november-93CH-5676492
This article reports on a Form 4 filing for Cytokinetics Inc, detailing a transaction by Fady Ibraham Malik, EVP of Research & Development, on November 3. The filing is an insider trading disclosure, providing transparency regarding executive stock movements. The core content is the announcement of this specific Form 4 filing.

Cytokinetics Reports Third Quarter 2026 Financial Results and Provides Business Update

https://www.manilatimes.net/2026/11/05/tmt-newswire/globenewswire/cytokinetics-reports-third-quarter-2026-financial-results-and-provides-business-update/2462157
Cytokinetics reported strong third-quarter 2026 financial results, driven by MYQORZO® (aficamten) net product revenue of $44.5 million. The company announced plans to submit a Supplemental NDA for aficamten in non-obstructive HCM in Q4 2026 and a Type II Variation in the EU in early 2027, aiming for aficamten to become the first cardiac myosin inhibitor approved across the full spectrum of HCM. Cytokinetics ended the quarter with approximately $1.6 billion in cash, cash equivalents, and investments.
Advertisement

Cytokinetics evp Fady Malik sells $220,255 in shares, exercises options By Investing.com

https://ca.investing.com/news/stock-market-news/cytokinetics-evp-fady-malik-sells-220255-in-shares-exercises-options-93CH-4927080
Fady Malik, Executive Vice President of Research & Development at Cytokinetics Inc., sold $220,255 worth of company shares on November 3, 2026, after exercising non-qualified stock options. The sale occurred while Cytokinetics' stock trades near its 52-week low, though InvestingPro analysis suggests it is undervalued. The company remains unprofitable but is the subject of several positive analyst ratings and strategic developments concerning its product, MYQORZO.

Cytokinetics (CYTK) executive Malik sold 3,500 shares for $220K at $62.93

https://www.quantisnow.com/insight/evp-research-development-malik-fady-ibraham-exercised-3500-shares-at-6770195
Fady Ibraham Malik, EVP Research & Development at Cytokinetics (CYTK), sold 3,500 shares for $220,000 at $62.93 per share on November 3, 2026. This transaction was part of a larger action where Malik also acquired 3,500 shares at $7.80 through the exercise of options. Following these transactions, Malik directly holds 153,902 shares of Cytokinetics.

Form 4 Cytokinetics Inc: Fady Ibraham Malik (EVP Research & Development) For: 3 November

https://ca.investing.com/news/stock-market-news/form-4-cytokinetics-inc-fady-ibraham-malik-evp-research--development-for-3-november-93CH-4927091
This article reports on a Form 4 filing for Cytokinetics Inc, detailing a transaction involving Fady Ibraham Malik, the EVP of Research & Development, on November 3rd. The brief notice provides key details about the insider trading activity without further elaboration.

Four live chats with Cytokinetics leaders are set for November; replays stay online 90 days.

https://www.stocktitan.net/news/CYTK/cytokinetics-to-participate-in-november-investor-6wdotp2h3kgv.html
Cytokinetics (CYTK) announced that its management team will participate in four investor conferences during November 2026, including fireside chats at Stifel, UBS, Jefferies, and Evercore conferences. Live webcasts of these events will be available on the company's website, with replays archived for 90 days. The company is a specialty cardiovascular biopharmaceutical company advancing a pipeline of potential new medicines for cardiac muscle dysfunction.

Cytokinetics EVP Fady Ibraham Executes 3,500 Stock Options at $7.80 and Sells Shares on November 3, 2026

https://kalkinemedia.com/us/news/announcements/cytokinetics-evp-fady-ibraham-executes-3500-stock-options-at-780-and-sells-shares-on-november-3-2026
Fady Ibraham, EVP of Research and Development at Cytokinetics Inc., executed 3,500 non-qualified stock options at $7.80 per share and simultaneously sold 3,500 common shares at $62.93 per share on November 3, 2026. These transactions were carried out under a Rule 10b5-1 trading plan. Following the transactions, Ibraham's direct ownership in the company stands at 153,902 common shares, with 12,886 remaining stock options.
Advertisement

Form 4 Cytokinetics Inc: Robert I. Blum (Director, President & CEO) For: 2 November

https://ca.investing.com/news/stock-market-news/form-4-cytokinetics-inc-robert-i-blum-director-president--ceo-for-2-november-93CH-4923680
This article reports on a Form 4 filing for Cytokinetics Inc., detailing a transaction by Robert I. Blum, who serves as a Director, President, and CEO of the company. The filing pertains to activity on November 2nd. Form 4 documents are used to disclose changes in beneficial ownership of securities by company insiders.

Cytokinetics CEO Robert Blum sells $471,075 in CYTK stock By Investing.com

https://za.investing.com/news/stock-market-news/cytokinetics-ceo-robert-blum-sells-471075-in-cytk-stock-93CH-4544404
Cytokinetics Inc. CEO Robert Blum sold 7,500 shares of CYTK common stock for $471,075 on November 2, 2026, while also acquiring the same number of shares by exercising non-qualified stock options. Following these transactions, Blum directly holds 278,544 shares, with the stock trading near its 52-week low. The company has also received several positive analyst ratings and price targets, indicating confidence in its product, MYQORZO.

Two talks will examine a drug's effects in people with a condition that thickens heart muscle.

https://www.stocktitan.net/news/CYTK/cytokinetics-announces-three-upcoming-presentations-at-the-hiv13e3dkqq5.html
Cytokinetics (CYTK) has announced three upcoming presentations at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions on November 6, 2026. Two late-breaking oral presentations will focus on the effects of aficamten on cardiac structure and function, and patient-reported health status in nonobstructive hypertrophic cardiomyopathy. A poster presentation will cover left ventricular systolic dysfunction during long-term aficamten therapy in obstructive hypertrophic cardiomyopathy.

Cytokinetics Announces Three Upcoming Presentations at the

https://www.globenewswire.com/news-release/2026/11/02/3393043/35409/en/cytokinetics-announces-three-upcoming-presentations-at-the-hypertrophic-cardiomyopathy-medical-society-hcms-scientific-sessions-held-in-collaboration-with-the-american-heart-associ.html
Cytokinetics, Incorporated (Nasdaq: CYTK) announced three upcoming presentations, including two late-breaking oral abstracts and one poster, at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions in collaboration with the American Heart Association Scientific Sessions in Chicago on November 6, 2026. The presentations will detail the effects of aficamten on cardiac structure, function, and patient-reported health status in nonobstructive hypertrophic cardiomyopathy, as well as an analysis of left ventricular systolic dysfunction in long-term aficamten therapy for obstructive HCM. Cytokinetics plans to submit a Supplemental New Drug Application for aficamten in non-obstructive HCM in Q4 2026.

Cytokinetics CEO Robert Blum sells $471,075 in CYTK stock

https://www.investing.com/news/insider-trading-news/cytokinetics-ceo-robert-blum-sells-471075-in-cytk-stock-93CH-4993217
Cytokinetics CEO Robert Blum sold 7,500 shares of CYTK common stock for $471,075 on November 2, 2026, after acquiring an equal number of shares through stock option exercise. This transaction occurred while the stock was near its 52-week low, and analyst ratings on Cytokinetics have recently been positive, with several firms initiating or reiterating Buy/Outperform ratings and setting price targets significantly above current levels.
Advertisement

Bank of America Securities Remains a Buy on Kura Oncology (KURA)

https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/8573868/bank-of-america-securities-remains-a-buy-on-kura-oncology-kura/
Bank of America Securities analyst Jason Zemansky has reiterated a Buy rating on Kura Oncology (KURA) with a $31.00 price target. This recommendation comes despite a negative corporate insider sentiment, with increased insider selling activity in the past quarter, including a recent sale by the COO. Kura Oncology reported increased quarterly revenue but also a higher GAAP net loss compared to the previous year.

Learn Why The Bull Case For Cytokinetics Stock Could Change Following Canada Drug Approval

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cytk/cytokinetics/news/learn-why-the-bull-case-for-cytokinetics-stock-could-change-1
Cytokinetics (NasdaqGS:CYTK) recently received Health Canada approval for MYQORZO, expanding its global market presence for treating obstructive hypertrophic cardiomyopathy. While this approval strengthens the operational thesis for the company, Cytokinetics remains loss-making with high R&D and commercial expenses. Investors are now focused on upcoming earnings on November 4th and the initial commercial performance of MYQORZO to see if it can help close the gap against significant annual losses.

Cytokinetics (CYTK) Could Be 43% Undervalued Following Health Canada Approval

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cytk/cytokinetics/news/cytokinetics-cytk-could-be-43-undervalued-following-health-c
Cytokinetics (CYTK) recently received Health Canada authorization for MYQORZO, expanding its global presence for the hypertrophic cardiomyopathy treatment. Despite a recent share price pullback of 23.8% over 90 days, the company is viewed as 43% undervalued with a fair value of $107.80, driven by long-range revenue projections and a growing pipeline beyond MYQORZO. Investors are advised to examine the underlying data and risks associated with commercial uptake and R&D spending.

Cytokinetics (CYTK) Could Be 43% Undervalued Following Health Canada Approval

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cytk/cytokinetics/news/cytokinetics-cytk-could-be-43-undervalued-following-health-c/amp
Cytokinetics (CYTK) has received Health Canada approval for MYQORZO, expanding its global presence for the hypertrophic cardiomyopathy treatment. Despite a recent share price pullback of 23.8% over 90 days, the company is seen as 43% undervalued, with a fair value estimated at $107.80 against its current $61.28. This valuation is based on long-range revenue and margin assumptions, supported by ongoing investments in its pipeline.

Cytokinetics Must Show MyCORSO Launch Can Outrun Summer Slowdown As Stock Slides 25%

https://finviz.com/news/409440/cytokinetics-must-show-mycorso-launch-can-outrun-summer-slowdown-as-stock-slides-25
Cytokinetics (CYTK) faces an "odd disconnect" as its stock has fallen 25% despite a successful launch of its heart drug, myCORSO, and a clear regulatory path for a second indication. As the company prepares for its third-quarter report on November 4, investors are focused on whether myCORSO's launch momentum continued through the summer slowdown, with analysts expecting a loss of $1.50 per share and revenue of $42.0 million. The report will also provide updates on the European launch and a planned supplemental filing for non-obstructive HCM, crucial factors for the company's long-term case.
Advertisement

How Cytokinetics Incorporated (CYTK) Affects Rotational Strategy Timing

https://news.stocktradersdaily.com/news_release/1/How_Cytokinetics_Incorporated_CYTK_Affects_Rotational_Strategy_Timing_102726024601_1793126761.html
This article analyzes Cytokinetics Incorporated (CYTK) using AI models to provide trading strategies and multi-timeframe signal analysis. It highlights weak near-term sentiment despite long-term strength and identifies specific entry, target, and stop-loss zones for position trading, momentum breakout, and risk hedging strategies. The analysis also details support and resistance levels across different time horizons.

How Cytokinetics Incorporated (CYTK) Affects Rotational Strategy Timing

https://news.stocktradersdaily.com/news_release/24/How_Cytokinetics_Incorporated_CYTK_Affects_Rotational_Strategy_Timing_102726024601_1793126761.html
This article analyzes Cytokinetics Incorporated (CYTK) and its impact on rotational strategy timing, highlighting weak near-term sentiment but strong long-term prospects. It presents three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis also includes multi-timeframe signal strength, support, and resistance levels.

Cytokinetics, Incorporated Estimates – NASDAQ:CYTK

https://www.tradingview.com/symbols/NASDAQ-CYTK/financials-estimates/
This article from TradingView provides an overview of Cytokinetics, Incorporated (NASDAQ: CYTK) financial estimates. It highlights actual and estimated financial data across income statements, balance sheets, cash flow, and valuation metrics, allowing users to compare actual results with analyst projections and observe trends. The content is presented as a resource for financial analysis, emphasizing that it is not investment advice and encourages individual research.

Canada Drug Approval Might Change The Case For Investing In Cytokinetics Stock (CYTK)

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cytk/cytokinetics/news/canada-drug-approval-might-change-the-case-for-investing-in
Cytokinetics recently received Health Canada authorization for MYQORZO (aficamten) to treat obstructive hypertrophic cardiomyopathy, a move supported by positive Phase 3 data. This approval reinforces the drug's consistent labeling across major markets and supports the narrative that MYQORZO could become a significant cardiomyopathy franchise anchor. The company is also planning to file a supplemental new drug application for aficamten in non-obstructive HCM, which could further broaden its market reach, though operational execution and managing cash burn remain key risks for the currently loss-making business.

Cytokinetics, Incorporated (CYTK) Stock Forecasts

https://ca.finance.yahoo.com/research/reports/ARGUS_4769_QuantitativeReport_1792540800000
Argus has raised its target price for Cytokinetics, Inc. (CYTK) to $54.00. The biopharmaceutical company is currently trading at $61.23 and is focused on developing muscle activators and inhibitors for debilitating diseases. This report provides a quantitative analysis for investors.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement